NGC Update Service: May 11, 2015 ▲ National Institute for Health and Care Excellence (NICE)

NGC Update Service: May 11, 2015

National Institute for Health and Care Excellence (NICE)

• Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism.

• Dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (part review of technology appraisal guidance 88). This updates a previously published guideline summary.

• Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA 142). This updates a previously published guideline summary.

• Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196). This updates a previously published guideline summary.